TICKERNERD
Menu
PHVSPHVSHealthcare · Biotechnology

PHVS Stock Forecast: Pharvaris NV Price Predictions for 2026-2027

Last close, 4 Nov 2026
$34
−1.29% on the day

The 14 Wall Street analysts covering Pharvaris NV hold a median 12-month price target of $60 — +75.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 3 Nov 2026 — in the lower half.

Market cap
$2.4B
Ticker Nerd rank
41/ 100
Median analyst target
$60
Analysts covering
14
Revenue$0.0
Operating income−$50.8M
Net income−$47.8M
Free cash flow−$37.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.6%
1M
+10.1%
YTD
+23.7%
1Y
+58.6%
From 52W high
−11.7%
From 52W low
+59.0%
$22
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pharvaris NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
41/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
86
Momentum
82
Value
69
Growth
50
Accruals
46
Quality
35
Size
32
Revisions
31
Issuance
29

Volatility (86): The share price has been relatively steady.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PHVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26PHVSHigh $79Median $60Low $41

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $41Median $60High $79

The green dot is the last close — the median target sits +75.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
23 Oct 2026B of A SecuritiesUpgradeBuy$44
10 Sept 2026GuggenheimMaintainsBuy$40 → $44
10 Sept 2026GuggenheimMaintainsBuy—
9 Sept 2026CitizensMaintainsMarket Outperform—
9 Sept 2026CitizensMaintainsMarket Outperform$75 → $79
9 Sept 2026Leerink PartnersMaintainsOutperform$50 → $65
9 Sept 2026Leerink PartnersMaintainsOutperform—
9 Sept 2026Morgan StanleyMaintainsOverweight—
9 Sept 2026Morgan StanleyMaintainsOverweight$46 → $62
9 Sept 2026RBC CapitalMaintainsOutperform—
9 Sept 2026RBC CapitalMaintainsOutperform$52 → $62
9 Sept 2026WedbushMaintainsOutperform$42 → $50
9 Sept 2026WedbushMaintainsOutperform—
9 Sept 2026Wells FargoMaintainsOverweight—
9 Sept 2026Wells FargoMaintainsOverweight$55 → $65
8 Sept 2026HC Wainwright & Co.ReiteratesBuy—
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$60
8 Sept 2026WedbushReiteratesOutperform$42
8 Sept 2026WedbushReiteratesOutperform—
13 Aug 2026CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PHVS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PHVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Pharvaris NV returned +58.6% against +14.8% for the S&P 500, dividends included.

PHVS vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26PHVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PHVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
9
Fundamentals

Pharvaris NV (PHVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.7×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
7.2×

Cheaper than 13% of US stocks

EV / EBITDA
−11.7×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−70.5%

Higher than 17% of US stocks

Return on assets
−42.3%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pharvaris NV (PHVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pharvaris NV has a market value of $2.4B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$170.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$155.3M.

  • Shares outstanding: 69.9M.

  • Trailing P/E: −11.7×; forward P/E: −11.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Pharvaris NV employs 148 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

PHVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHVSPharvaris NV$2.4B41
IMNMImmunome, Inc.$2.4B35
ADMAADMA Biologics, Inc.$2.5B56
NAMSNewAmsterdam Pharma Co. NV$2.3B45
CLDXCelldex Therapeutics, Inc.$2.3B25
XNCRXencor, Inc.$2.3B80
BHVNBiohaven Ltd.$2.3B57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pharvaris NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHVS news & analysis

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

GlobeNewsWire · 29 Oct 2026positive

Pharvaris said pivotal Phase 3 CHAPTER-3 data were selected for a late-breaking oral presentation at the ACAAI 2026 Annual Scientific Meeting on Saturday, November 14. The headline also notes that the company will present clinical and real-world data.

Why it matters — The presentation provides PHVS watchers an opportunity to follow the company’s clinical and real-world data disclosures at the meeting.

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Benzinga · 23 Oct 2026positive

Bank of America Securities upgraded Pharvaris N.V. on Friday, citing an attractive entry point and clinical risk that it viewed as largely removed.

Why it matters — The upgrade and its stated rationale are relevant to PHVS watchers following analyst views and perceived clinical risk.

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

GlobeNewsWire · 5 Oct 2026neutral

A real-world analysis on hereditary angioedema (HAE) disease experience and gaps in treatment satisfaction was published in Advances in Therapy, highlighting opportunities for further improvement in treatment use and adherence despite the availability of multiple long-term prophylaxis and on-demand treatment options.

Why it matters — The analysis identifies unmet needs and gaps in HAE treatment satisfaction that a PHVS watcher would find relevant to the competitive landscape of therapies in this space.

FAQ

Frequently asked questions about PHVS stock

What is the PHVS stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Pharvaris NV have a median 12-month price target of $60, with estimates ranging from $41 to $79. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHVS stock a buy right now?

Of the 14 analysts covering Pharvaris NV, 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pharvaris NV 41 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHVS?

As at 3 Nov 2026, Pharvaris NV ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (86 of 100).

Will PHVS stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +75.3% from the last close, and Ticker Nerd's factor model ranks Pharvaris NV 41 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHVS stock forecast for 2030?

No analyst covering Pharvaris NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $79 over the next 12 months.

How has PHVS stock performed over the past year?

Pharvaris NV returned +58.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pharvaris NV do?

Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases.

What is the latest news on PHVS?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting". Pharvaris said pivotal Phase 3 CHAPTER-3 data were selected for a late-breaking oral presentation at the ACAAI 2026 Annual Scientific Meeting on Saturday, November 14. The headline also notes that the company will present clinical and real-world data.

Company

About Pharvaris NV.

Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases. The company’s core work centers on bradykinin B2 receptor antagonists designed to address hereditary angioedema and related angioedema conditions through on-demand and preventive treatment options. Its current pipeline includes formulations intended for acute attack management as well as longer-acting prophylactic use, reflecting a portfolio built around differentiated oral approaches in a market still served by injectable and other traditional therapies. Pharvaris operates as a research-driven drug developer with activities spanning clinical development, regulatory engagement, and eventual commercialization of therapies for underserved patient populations. The company is headquartered in Zug, Switzerland.

CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A. · 148 employees · Switzerland · https://pharvaris.com